Martine Rothblatt Sells 9,500 Shares of United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the company’s stock in a transaction on Friday, March 13th. The stock was sold at an average price of $538.00, for a total transaction of $5,111,000.00. Following the completion of the sale, the chief executive officer owned 130 shares of the company’s stock, valued at $69,940. This represents a 98.65% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

United Therapeutics Price Performance

United Therapeutics stock opened at $527.00 on Friday. United Therapeutics Corporation has a one year low of $266.98 and a one year high of $548.12. The company’s fifty day moving average price is $489.57 and its two-hundred day moving average price is $466.41. The company has a market capitalization of $23.10 billion, a price-to-earnings ratio of 18.89, a PEG ratio of 1.91 and a beta of 0.84.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share for the quarter, topping analysts’ consensus estimates of $6.78 by $0.92. The company had revenue of $790.20 million during the quarter, compared to analysts’ expectations of $814.80 million. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The business’s quarterly revenue was up 7.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $6.19 earnings per share. As a group, sell-side analysts anticipate that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

Key Stories Impacting United Therapeutics

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Analysts have largely raised targets and maintained buy/outperform views, supporting valuation — multiple firms (UBS, RBC, TD Cowen, Cantor Fitzgerald, Jefferies) recently lifted targets or reiterated buy ratings, keeping the consensus at a moderate buy. MarketBeat UTHR coverage
• Positive Sentiment: Solid recent quarterly results: UTHR reported an EPS beat (reported $7.70 vs. $6.78 consensus) with healthy margins, which supports earnings momentum despite a modest revenue miss. Earnings summary
• Neutral Sentiment: Sector comparison pieces (e.g., CPRX vs UTHR) are circulating; these may attract relative‑value buyers but are not company‑specific catalysts. Zacks comparison
• Neutral Sentiment: Institutional ownership remains very high (~94%) with some recent modest position changes by funds — this can mute volatility from retail flows but also concentrates sell pressure when insiders sell. MarketBeat institutional note
• Negative Sentiment: CEO Martine Rothblatt sold a large block in mid‑March — roughly 9,500 shares at about $533–$538/share (≈$5.1M), with filings showing a substantial reduction in her direct stake; such headline insider selling typically pressures the stock. SEC filing
• Negative Sentiment: EVP Paul A. Mahon sold 8,300 shares at an average ~$529.95 (≈$4.4M) on March 19, further adding to sell‑side pressure from insiders. SEC filing

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in UTHR. Rockefeller Capital Management L.P. boosted its position in shares of United Therapeutics by 10.6% in the fourth quarter. Rockefeller Capital Management L.P. now owns 1,323 shares of the biotechnology company’s stock valued at $645,000 after acquiring an additional 127 shares during the period. Corient Private Wealth LLC increased its position in United Therapeutics by 13.5% during the fourth quarter. Corient Private Wealth LLC now owns 19,248 shares of the biotechnology company’s stock worth $9,379,000 after acquiring an additional 2,289 shares during the period. Rehmann Capital Advisory Group increased its position in United Therapeutics by 9.8% during the fourth quarter. Rehmann Capital Advisory Group now owns 3,619 shares of the biotechnology company’s stock worth $1,767,000 after acquiring an additional 324 shares during the period. Tobam raised its stake in United Therapeutics by 28.9% during the 4th quarter. Tobam now owns 9,857 shares of the biotechnology company’s stock valued at $4,803,000 after purchasing an additional 2,211 shares during the last quarter. Finally, Wick Capital Partners LLC acquired a new position in United Therapeutics during the 4th quarter valued at $297,000. 94.08% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on UTHR shares. Wells Fargo & Company increased their price target on United Therapeutics from $423.00 to $466.00 and gave the company an “equal weight” rating in a report on Thursday, February 26th. Oppenheimer boosted their price objective on shares of United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a research note on Thursday, February 26th. Jefferies Financial Group reaffirmed a “buy” rating on shares of United Therapeutics in a report on Monday, March 2nd. Weiss Ratings reiterated a “buy (b)” rating on shares of United Therapeutics in a research note on Monday, December 29th. Finally, UBS Group lifted their target price on shares of United Therapeutics from $655.00 to $705.00 and gave the stock a “buy” rating in a report on Thursday, March 5th. Nine investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $548.09.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.